[Therapeutic advances in lung cancer]
Related Experiment Video
Updated: Feb 1, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Solenn Brosseau1, Charles Naltet1, Valérie Gounant1
1Service d'oncologie thoracique, CIC1425/ CLIP2 Paris-Nord, université Paris- Diderot, hôpital Bichat-Claude-Bernard, AP-HP, Paris, France.
Abstract:
Therapeutic advances in lung cancer. The molecular dissection of lung cancers led to the development of new oral targeted therapies, mainly kinase inhibitors, in 15% of non-small cell lung cancer patients of which tumors exhibit oncogenic activating mutations or gene translocations involving genes encoding for kinases. The overall survival of patients with such tumors with addictive gene alterations reaches several years with those kinase inhibitors nowadays, with new generation drugs in second or third-line settings, extending such survival by acting on resistance mutations emerging after first-line therapy. Individual screening of lung cancer using low dose CT-scanner in smoker patients aged 55-74 years, allows the finding of small stage IA cancer nodules, with long-term survival rates exceeding 80% at 5 years. For such small tumors, patients take advantage of minimally invasive surgery, such as sub-lobar resection, video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS). Such small tumors could also be cured by stereotactic ablative radiotherapy. At last, the monoclonal antibodies targeting immune checkpoint proteins, currently consist of the new therapeutic revolution in 20 to 30% of patients with tumors highly expressing the PD-1/PD-L1 proteins, with a plateau of long term survival, at the cost of immune side effects which do not significantly impair quality of life in most treated patients.
Insights
Advances in lung cancer treatment include targeted therapies for specific mutations and immune checkpoint inhibitors for PD-1/PD-L1 positive tumors. Early detection via low-dose CT scans improves survival rates for early-stage lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Radiology
Background:
- Lung cancer treatment has evolved significantly with molecular understanding.
- Targeted therapies and immunotherapies have emerged as key treatment modalities.
- Early detection strategies improve patient outcomes.
Purpose of the Study:
- To review recent therapeutic advances in lung cancer treatment.
- To highlight the impact of targeted therapies and immunotherapies.
- To discuss the role of early detection and minimally invasive procedures.
Main Methods:
- Review of molecular dissection of lung cancers.
- Analysis of targeted therapies (kinase inhibitors).
- Evaluation of immunotherapies (monoclonal antibodies targeting PD-1/PD-L1).
- Assessment of early detection methods (low-dose CT screening).
- Review of surgical and radiotherapeutic approaches for early-stage disease.
Main Results:
- Targeted kinase inhibitors benefit approximately 15% of non-small cell lung cancer patients with specific mutations, extending survival.
- Newer generation inhibitors address resistance mutations, further improving outcomes.
- Low-dose CT screening in high-risk individuals detects early-stage lung cancer, offering >80% 5-year survival with minimally invasive treatments.
- Immunotherapies (anti-PD-1/PD-L1) provide long-term survival benefits for 20-30% of patients, with manageable side effects.
Conclusions:
- Molecularly targeted therapies and immunotherapies represent significant advances in lung cancer treatment.
- Early detection through screening and prompt, minimally invasive interventions are crucial for improving survival.
- Personalized medicine approaches are transforming lung cancer care, offering hope for longer and better quality of life.
Related Concept Videos
01:47Lung Capacity
01:13Therapeutic Index
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...